Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-205 in Duchenne Muscular Dystrophy
NCT04587908Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Nov 2020
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pizuglanstat in Duchenne muscular dystrophy (DMD), sponsored by Taiho Pharmaceutical Co., Ltd.. Started Nov 2020; status: completed.
02
Drugs
pizuglanstat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT04587908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04587908.